Updated on 2025/05/19

写真a

 
Hiroki Abe
 
Organization
Graduate School of Medicine Department of Medicine Physiology Associate Professor
School of Medicine Medical Course
Title
Associate Professor
Profile

学位:医学博士、医師資格:脳神経内科専門医・指導医

臨床神経学の立場から、グルタミン酸AMPA受容体を介して実現される神経可塑性機構に基づいた神経疾患の診断法・治療法の開発を目指している。神経情報伝達の場であるシナプスにおいて、シナプス後膜に発現するグルタミン酸AMPA受容体は神経可塑性を担う分子の一つとして知られている (1)。先行する基礎研究に基づき (2, 3), 2012年からAMPA受容体シナプス後膜移行促進薬 (T-817 : edonerpic maleate)のリハビリテーション促進効果を、げっ歯類、非ヒト霊長類、ヒトで検証している (4, 5)。並行して、neurorehabilitationを可能とする主要な神経回路の同定を[11C]K-2 AMPA受容体PET (6)を用いて試みている。2019年以降、神経変性病態へのAMPA受容体発現変化の関与を明らかにすることを目的としてパーキンソン病、認知症を対象とした臨床研究を展開している (2025年3月)。

1. R. Malinow and R. C. Malenka, Annu. Rev. Neurosci. 25, 103-126 (2002).

2. T. Takahashi et al., Science. 299, 1585-1588 (2003)

3. S. Jitsuki et al., Neuron. 69, 780-792 (2011)

4. H. Abe et al., Science. 360, 50-57 (2018). 

5. K. Uramaru, H. Abe et al., Brain Communications, 7, fcaf036 (2025)

6. T. Miyazaki et al., Nat. Med. 26, 281-288 (2020).

External link

Degree

  • 博士(医学) ( 2019.4   横浜市立大学 )

Research Interests

  • plasticity

Research Areas

  • Life Science / Neurology

Education

Research History

  • 横浜市立大学医学群医学部医学科   生理学   准教授

    2023.4

      More details

  • 国立研究開発法人 国立精神・神経医療研究センター病院   脳神経内科診療部   非常勤医師

    2019.10 - 2022.3

      More details

  • 横浜市立大学医学群医学部医学科   生理学   助教

    2019.5 - 2023.3

      More details

  • National Center of Neurology and Psychiatry

    2017.4 - 2019.8

      More details

  • 横浜市立大学医学群医学部医学科   生理学   助手

    2016.4 - 2019.4

      More details

  • 横浜市立大学医学群医学部医学科   生理学   特任助手

    2013.9 - 2016.3

      More details

  • Yokohama City University   Hospital

    2012.4 - 2013.8

      More details

  • Yokohama City University   Hospital

    2011.4 - 2012.3

      More details

  • Yokohama City University   Medical Center

    2010.4 - 2011.3

      More details

▼display all

Professional Memberships

▼display all

Papers

  • Edonerpic maleate enhances functional recovery from spinal cord injury with cortical reorganization in non-human primates Reviewed

    Koichi Uramaru, Hiroki Abe, Waki Nakajima, Wataru Ota, Michiaki Suzuki, Osamu Yokoyama, Tetsuya Yamamoto, Yukio Nishimura, Takuya Takahashi

    Brain Communications   7 ( 2 )   2025.3

     More details

    Language:English  

    researchmap

  • CRMP2-binding compound, edonerpic maleate, accelerates motor function recovery from brain damage. Reviewed

    Abe H, Jitsuki S, Nakajima W, Murata Y, Jitsuki-Takahashi A, Katsuno Y, Tada H, Sano A, Suyama K, Mochizuki N, Komori T, Masuyama H, Okuda T, Goshima Y, Higo N, Takahashi T

    Science   360   50 - 57   2018.4

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    researchmap

  • Characterization of patients with major psychiatric disorders with AMPA receptor positron emission tomography. Reviewed International journal

    Mai Hatano, Waki Nakajima, Hideaki Tani, Hiroyuki Uchida, Tomoyuki Miyazaki, Tetsu Arisawa, Yuuki Takada, Sakiko Tsugawa, Akane Sano, Kotaro Nakano, Tsuyoshi Eiro, Hiroki Abe, Akira Suda, Takeshi Asami, Akitoyo Hishimoto, Nobuhiro Nagai, Teruki Koizumi, Shinichiro Nakajima, Shunya Kurokawa, Yohei Ohtani, Kie Takahashi, Yuhei Kikuchi, Taisuke Yatomi, Shiori Honda, Masahiro Jinzaki, Yoji Hirano, Ryo Mitoma, Shunsuke Tamura, Shingo Baba, Osamu Togao, Hirotaka Kosaka, Hidehiko Okazawa, Yuichi Kimura, Masaru Mimura, Takuya Takahashi

    Molecular psychiatry   2024.10

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Synaptic phenotypes in living patients with psychiatric disorders are poorly characterized. Excitatory glutamate α-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid receptor (AMPAR) is a fundamental component for neurotransmission. We recently developed a positron emission tomography (PET) tracer for AMPAR, [11C]K-2, the first technology to visualize and quantify AMPARs density in living human brain. In this study, we characterized patients with major psychiatric disorders with [11C]K-2. One hundred forty-nine patients with psychiatric disorders (schizophrenia, n = 42; bipolar disorder, n = 37; depression, n = 35; and autism spectrum disorder, n = 35) and 70 healthy participants underwent a PET scan with [11C]K-2 for measurement of AMPAR density. We detected brain regions that showed correlation between AMPAR density and symptomatology scores in each of four disorders. We also found brain areas with significant differences in AMPAR density between patients with each psychiatric disorder and healthy participants. Some of these areas were observed across diseases, indicating that these are commonly affected areas throughout psychiatric disorders. Schizophrenia, bipolar disorder, depression, and autism spectrum disorder are uniquely characterized by AMPAR distribution patterns. Our approach to psychiatric disorders using [11C]K-2 can elucidate the biological mechanisms across diseases and pave the way to develop novel diagnostics and therapeutics based on the synapse physiology.

    DOI: 10.1038/s41380-024-02785-1

    PubMed

    researchmap

  • Edonerpic maleate prevents epileptic seizure during recovery from brain damage by balancing excitatory and inhibitory inputs. Reviewed International journal

    Yuki Katsuno, Susumu Jitsuki, Wataru Ota, Tomomi Yamanoue, Hiroki Abe, Takuya Takahashi

    Frontiers in neural circuits   18   1492043 - 1492043   2024

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Functional recovery from brain damage, such as stroke, is a plastic process in the brain. The excitatory glutamate α-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid receptor (AMPAR) plays a crucial role in neuronal functions, and the synaptic trafficking of AMPAR is a fundamental mechanism underlying synaptic plasticity. We recently identified a collapsin response mediator protein 2 (CRMP2)-binding compound, edonerpic maleate, which augments rehabilitative training-dependent functional recovery from brain damage by facilitating experience-driven synaptic delivery of AMPARs. In animals recovering from cryogenic brain injury, a potential compensatory area adjacent to the injured region was observed, where the injection of CNQX, an AMPAR antagonist, significantly attenuated functional recovery. In the compensatory brain area of animals recovering from cryogenic injury, the administration of edonerpic maleate enhanced both excitatory and inhibitory synaptic inputs at pyramidal neurons. In contrast, recovered animals that did not receive the drug exhibited augmentation of only excitatory synaptic input. The threshold of picrotoxin-induced epileptic seizure in recovered animals without edonerpic maleate treatment was lower than in intact animals and recovered animals with edonerpic maleate. Thus, edonerpic maleate enhances motor function recovery from brain damage by balancing excitatory and inhibitory synaptic inputs, which helps prevent epileptic seizures during recovery.

    DOI: 10.3389/fncir.2024.1492043

    PubMed

    researchmap

  • Anti-epileptic drug use and subsequent degenerative dementia occurrence. Reviewed International journal

    Naoki Ikegaya, Honoka Nakamura, Yutaro Takayama, Yohei Miyake, Takahiro Hayashi, Masaki Sonoda, Mitsuru Sato, Kensuke Tateishi, Jun Suenaga, Masao Takaishi, Yu Kitazawa, Misako Kunii, Hiroki Abe, Tomoyuki Miyazaki, Tetsuaki Arai, Manabu Iwasaki, Takayuki Abe, Tetsuya Yamamoto

    Alzheimer's & dementia (New York, N. Y.)   10 ( 3 )   e70001   2024

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    INTRODUCTION: The use of anti-epileptic drugs (AEDs) in degenerative dementia (DD) remains uncertain. We aimed to evaluate the association of early AED administration with subsequent DD occurrence. METHODS: Using a large nationwide database, we enrolled patients newly diagnosed with epilepsy from 2014 to 2019 (n = 104,225), and using propensity score matching, we divided them into treatment (those prescribed AEDs in 2014) and control groups. The primary outcome was subsequent DD occurrence in 2019. RESULTS: Overall, 4489 pairs of patients (2156 women) were matched. The odds ratio (treatment/control) for DD occurrence was 0.533 (95% confidence interval: 0.459-0.617). The DD proportions significantly differed between the treatment (340/4489 = 0.076) and control (577/4489 = 0.129) groups. DISCUSSION: Among patients newly diagnosed with epilepsy, compared to non-use, early AED use was associated with a lower occurrence of subsequent DD. Further investigations into and optimization of early intervention for epilepsy in DD are warranted. HIGHLIGHTS: Anti-epileptic drug (AED) use before epilepsy diagnosis was linked with a lower subsequent degenerative dementia (DD) occurrence.Identifying the epileptic phenotype was crucial for justifying early AED use in DD.AED use with an epilepsy diagnosis did not pose an additional risk of DD.The potential contribution of combination drug therapy to the strategy was noted.

    DOI: 10.1002/trc2.70001

    PubMed

    researchmap

  • Translational medicine of the glutamate AMPA receptor.

    Tomoyuki Miyazaki, Hiroki Abe, Hiroyuki Uchida, Takuya Takahashi

    Proceedings of the Japan Academy. Series B, Physical and biological sciences   97 ( 1 )   1 - 21   2021

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Psychiatric and neurological disorders severely hamper patient's quality of life. Despite their high unmet needs, the development of diagnostics and therapeutics has only made slow progress. This is due to limited evidence on the biological basis of these disorders in humans. Synapses are essential structural units of neurotransmission, and neuropsychiatric disorders are considered as "synapse diseases". Thus, a translational approach with synaptic physiology is crucial to tackle these disorders. Among a variety of synapses, excitatory glutamatergic synapses play central roles in neuronal functions. The glutamate α-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid receptor (AMPAR) is a principal component of glutamatergic neurotransmission; therefore, it is considered to be a promising translational target. Here, we review the limitations of current diagnostics and therapeutics of neuropsychiatric disorders and advocate the urgent need for the promotion of translational medicine based on the synaptic physiology of AMPAR. Furthermore, we introduce our recent translational approach to these disorders by targeting at AMPARs.

    DOI: 10.2183/pjab.97.001

    PubMed

    researchmap

  • Riluzole-induced interstitial lung disease is a rare and potentially life-threatening adverse event successfully treated with high-dose steroid therapy: Case reports and review of the literature. Reviewed International journal

    Yuji Saitoh, Yohei Aoshima, Taiji Mukai, Hiroki Abe, Hajime Ariga, Madoka Mori-Yoshimura, Tomoko Okamoto, Yuji Takahashi

    Journal of the neurological sciences   410   116650 - 116650   2020.3

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Riluzole (RZ)-induced interstitial lung disease (RZ-ILD) is a rare and potentially life-threatening adverse event in amyotrophic lateral sclerosis (ALS) patients, which is rarely reported. Therefore, the optimal treatment for RZ-ILD is unclear. We describe herein three Japanese cases of ALS complicated with RZ-ILD, of which two were successfully treated with high-dose steroid therapy. In our all ALS cases with RZ-ILD, the duration of RZ exposure until RZ-ILD onset was within 2 months. All three cases showed respiratory symptoms, dorsal predominant ground-glass opacities by imaging analysis, and abnormal laboratory findings associated with interstitial lung diseases, such as Krebs von den Lungen-6 and surfactant protein-D. Intravenous high-dose steroid therapy together with the discontinuation of RZ in two cases with respiratory symptoms markedly ameliorated their symptoms and abnormal findings of RZ-ILD. One case showed mild respiratory symptoms compared with the others and recovered after the withdrawal of RZ only. According to previous case reports and our cases, RZ-ILD may develop 2 months after initiating RZ and exacerbate respiratory symptoms rapidly in ALS patients with severe respiratory muscle involvement or complicating aspiration pneumonia. Transient high-dose steroid therapy in addition to discontinuation of RZ might be a good therapeutic option for RZ-ILD.

    DOI: 10.1016/j.jns.2019.116650

    PubMed

    researchmap

  • Pharmacological Enhancement of Stroke Rehabilitation. Invited Reviewed International journal

    Hiroki Abe, Susumu Jitsuki, Takuya Takahashi

    Stroke   50 ( 11 )   3323 - 3329   2019.11

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1161/STROKEAHA.119.023720

    PubMed

    researchmap

  • Social isolation suppresses actin dynamics and synaptic plasticity through ADF/cofilin inactivation in the developing rat barrel cortex. Reviewed International journal

    Hirobumi Tada, Tomoyuki Miyazaki, Kiwamu Takemoto, Susumu Jitsuki, Waki Nakajima, Mayu Koide, Naoko Yamamoto, Akiko Taguchi, Honami Kawai, Kasane Komiya, Kumiko Suyama, Hiroki Abe, Akane Sano, Takuya Takahashi

    Scientific reports   7 ( 1 )   8471 - 8471   2017.8

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Exposure to a stressful environment early in life can cause psychiatric disorders by disrupting circuit formation. Actin plays central roles in regulating neuronal structure and protein trafficking. We have recently reported that neonatal isolation inactivated ADF/cofilin, the actin depolymerizing factor, resulted in a reduced actin dynamics at spines and an attenuation of synaptic α-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) receptor delivery in the juvenile rat medial prefrontal cortex (mPFC), leading to altered social behaviours. Here, we investigated the impact of neonatal social isolation in the developing rat barrel cortex. Similar to the mPFC study, we detected an increase in stable actin fraction in spines and this resulted in a decreased synaptic AMPA receptor delivery. Thus, we conclude that early life social isolation affects multiple cortical areas with common molecular changes.

    DOI: 10.1038/s41598-017-08849-3

    PubMed

    researchmap

▼display all

MISC

  • 【てんかん診療】てんかんにおけるAMPA受容体の可視化

    宮崎 智之, 阿部 弘基, 高橋 琢哉

    脳神経内科   96 ( 5 )   578 - 582   2022.5

     More details

    Language:Japanese   Publisher:(有)科学評論社  

    researchmap

  • Clinical Topics 機能性疾患 AMPA受容体PETの可能性

    阿部 弘基, 高橋 琢哉

    Annual Review神経   2021   344 - 353   2021.6

     More details

    Language:Japanese   Publisher:(株)中外医学社  

    researchmap

  • 【脳卒中運動麻痺へのアプローチ】リハビリテーション治療効果を促進する低分子化合物edonerpic maleateによる運動麻痺へのアプローチ

    阿部 弘基, 高橋 琢哉

    Journal of Clinical Rehabilitation   30 ( 6 )   589 - 595   2021.6

     More details

    Language:Japanese   Publisher:医歯薬出版(株)  

    researchmap

  • 神経疾患の「機能回復ネットワーク」の探索

    阿部 弘基, 高橋 琢哉

    Medical Science Digest   46 ( 10 )   634 - 637   2020.9

     More details

    Language:Japanese   Publisher:(株)ニュー・サイエンス社  

    根本的治療法が存在しない神経疾患では機能障害の後遺は避け難い。機能障害を改善・代償するには疾患の進行や再発を抑制する治療に加えて、リハビリテーションが重要である。近年、脳卒中に限らず、脊髄小脳変性症、パーキンソン病、多発性硬化症といった慢性進行性疾患でもリハビリテーション法の改良が試みられている。脳神経科学ではリハビリテーションによる機能回復は非障害脳領域における機能的再構築に依拠するとされてきたが、ヒト生体脳において疾患毎の機能回復能の神経生理学的理解は不十分である。我々は、急性脳損傷モデルにおいて、グルタミン酸AMPA受容体のシナプス後膜への移行促進がリハビリテーションによる運動機能回復を促進することを薬理学的に示した。現在はこの研究に動機づけられ、PET画像で得られるAMPA受容体発現密度分布を手掛かりとして、リハビリテーションを可能とする「機能回復ネットワーク」の疾患横断的解明に取り組んでいる。(著者抄録)

    researchmap

  • 脳卒中後リハビリテーションを促進する新規低分子化合物

    阿部弘基, 高橋琢哉

    医学のあゆみ   268 ( 7 )   585 - 586   2019.2

     More details

    Language:Japanese   Publishing type:Article, review, commentary, editorial, etc. (trade magazine, newspaper, online media)  

    researchmap

  • 精神科領域の用語解説 AMPA受容体

    阿部弘基, 高橋琢哉

    分子精神医学   18 ( 3 )   54(162) - 55(163)   2018.7

     More details

    Language:Japanese   Publishing type:Article, review, commentary, editorial, etc. (other)  

    researchmap

▼display all

Presentations

  • 未踏峰直登の医学研究を目指すには -AMPA受容体研究に基づいた臨床開発のこれまでとこれから- Invited

    阿部弘基

    横浜市立大学附属病院 次世代臨床研究センター 臨床研究セミナー (横浜)  2025.2 

     More details

    Language:Japanese   Presentation type:Public lecture, seminar, tutorial, course, or other speech  

    researchmap

  • 18F-FDG PETが病勢を反映した首下がりの70歳女性例

    阿部弘基, 東山 雄一, 上木 英人, 岩橋 幸子, 鈴木 ゆめ, 田中 章景

    第206回日本神経学会関東・甲信越地方会(東京)  2013.9 

     More details

    Language:Japanese   Presentation type:Oral presentation (general)  

    researchmap

  • 下膵臓動脈瘤破裂による急性腹症の1例

    阿部弘基, 大井康史, 鈴木弘之, 山田俊介, 安久正哲, 土井智喜, 馬場紀行, 濱田幸一, 小菅宇之, 森脇義弘, 田原良雄, 鈴木範行, 森村尚登, 竹林茂生

    日本救急医学会関東地方会(横浜)  2011.2 

     More details

    Language:Japanese   Presentation type:Oral presentation (general)  

    researchmap

  • カニクイザル内包出血作製および運動障害評価法の確立

    中島和希, 阿部弘基, 村田 弓, 肥後範行, 奥田智博, 高橋琢哉

    第41回日本脳卒中学会総会(札幌)  2016.4 

     More details

    Presentation type:Poster presentation  

    researchmap

  • 脳損傷周辺領域に可塑的変化を誘導しリハビリテーション効果を促進する低分子化合物の同定

    阿部弘基, 実木 亨, 小森 隆司, 荒 若菜, 水口 愛香, 佐野 亜加根, 須山 紅美子, 奥田 智博, 田中 章景, 高橋 琢哉

    第33回日本神経治療学会総会  2015.10 

     More details

    Language:Japanese   Presentation type:Poster presentation  

    researchmap

  • 脳卒中後失語症回復過程における WAB改善度とAMPA受容体発現量の相関

    高田薫子, 高橋素彦, 浦野雅世, 中島和希, 阿部弘基

    第8回日本リハビリテーション医学会秋季学術集会 (岡山)  2024.11 

     More details

    Language:Japanese   Presentation type:Oral presentation (general)  

    researchmap

  • ステロイドパルス後の単純血漿交換療法による改善効果が電気生理学的検査に反映された中枢末梢連合脱髄症の53歳女性例

    阿部弘基, 坂本崇, 林幼偉, 金澤恭子, 岡本智子, 山本敏之, 高橋祐二

    第48回日本臨床神経生理学会学術大会(東京)  2018.10 

     More details

    Language:Japanese   Presentation type:Poster presentation  

    researchmap

  • 封入体筋炎による嚥下障害を合併したパーキンソン病68歳女性例

    阿部弘基, 斎藤勇二, 森まどか, 西野一三, 山本敏之, 髙橋祐二

    難病嚥下研究会第6回セミナー(東京)  2018.10 

     More details

    Language:Japanese   Presentation type:Oral presentation (general)  

    researchmap

  • 常圧水頭症の術後4年目から認知機能と歩行障害が悪化した神経核内封入体病の73歳男性

    阿部弘基, 齊藤勇二, 小松奏子, 齊藤裕子, 岩崎真樹, 山本敏之, 高橋祐二

    第228回日本神経学会関東・甲信越地方会(東京)  2019.3 

     More details

    Language:Japanese   Presentation type:Oral presentation (general)  

    researchmap

  • Detection of compensatory brain regions after brain damage using a novel PET tracer

    Hiroki Abe

    SABM2019 (International Symposium of Brain/MINDS – From Structure to Function) (Tokyo)  2019.1 

     More details

    Language:English   Presentation type:Poster presentation  

    researchmap

  • 失語症回復過程での[11C]K-2を用いたPETイメージング法によるAMPA受容体変化量

    高田薫子, 浦野雅世, 阿部弘基

    第59回日本リハビリテーション医学会学術集会(横浜)  2022.6 

     More details

    Language:Japanese   Presentation type:Oral presentation (general)  

    researchmap

  • Molecular imaging of functional recovery process aiming for a development of rehabilitation accelerating agent

    2019.7 

     More details

    Language:English   Presentation type:Poster presentation  

    researchmap

  • In vivo AMPA receptors PET imaging in Parkinson’s disease

    2023.8 

     More details

    Language:English   Presentation type:Poster presentation  

    researchmap

  • Edonerpic maleate accelerates recovery of upper limb function from spinal cord injury in nonhuman primates

    2023.3 

     More details

    Language:English   Presentation type:Poster presentation  

    researchmap

  • AMPA受容体シナプス移行促進作用を有する 機能回復促進薬の研究開発

    阿部弘基, 実木享, 中島和希, 村田弓, 有澤哲, 宮崎智之, 肥後範行, 浦丸浩一, 鈴木迪諒, 西村 幸男, 内山 侑紀, 道免 和久, 佐伯覚, 高田薫子, 前野豊, 中村 健, 高橋琢哉

    第65回日本神経学会学術大会(東京)  2024.5 

     More details

    Language:Japanese   Presentation type:Symposium, workshop panel (public)  

    researchmap

  • AMPA受容体シナプス移行促進作用を有する機能回復促進薬の研究開発 Invited

    阿部弘基

    第17回Motor Control研究会  2023.8 

     More details

    Language:Japanese   Presentation type:Oral presentation (invited, special)  

    researchmap

  • シナプス生理学に基づいた薬剤介入によるリハビリテーション促進法の研究開発 Invited

    ニューロリハビリテーション シンポジウム2018 「介入研究のフロンティア」(東京)  2018.11 

     More details

    Language:Japanese   Presentation type:Oral presentation (invited, special)  

    researchmap

  • A novel small low molecular compound, T-817-maleic-acid, accelerates motor function recovery from brain damage

    Abe H., Jitsuki S., Komori T., Nakajima W., Murata Y., Higo N., Okuda T., Takahashi T.

    Current Trends and Future Directions of Synaptic Plasticity Research(Baltimore)  2016.6 

     More details

    Language:English   Presentation type:Poster presentation  

    researchmap

  • 脳損傷周辺領域に可塑的変化を誘導しリハビリテーション効果を促進する低分子化合物の同定

    阿部弘基, 実木亨, 小森隆司, 水口愛香, 佐野亜加根, 須山紅美子, 奥田智博, 高橋琢哉

    第41回日本脳卒中学会総会(札幌)  2016.4 

     More details

    Language:Japanese   Presentation type:Poster presentation  

    researchmap

  • CRMP2 binding compound, T-817-maleic-acid, accelerates motor function recovery from brain damage

    Abe H., Jitsuki S., Takahashi T.

    Cold Spring Harbor Laboratory meeting : Axon guidance, synapse formation and regeneration (New York)  2016.9 

     More details

    Language:English   Presentation type:Oral presentation (general)  

    researchmap

  • 神経可塑性機構に基づいたリハビリテーション促進薬の研究開発

    阿部弘基, 実木亨, 中嶋和希, 村田弓, 増山仁, 小森隆司, 望月修征, 肥後範行, 奥田智博, 高橋琢哉

    第8回日本ニューロリハビリテーション学会 (富山)  2017.4 

     More details

    Language:Japanese   Presentation type:Oral presentation (general)  

    researchmap

  • CRMP2 binding compound, T-817-maleic-acid, accelerates motor function recovery from brain damage

    Abe H., Jitsuki S., Komori T., Nakajima W., Murata Y., Higo N., Okuda T., Takahashi T.

    Cold Spring Harbor Laboratory meeting : Neurodegenerative disease: Biology and Therapeutics (New York)  2016.11 

     More details

    Language:English   Presentation type:Poster presentation  

    researchmap

  • レボドパ・カルビドパ配合経腸用液(LCIG)による生活の変化

    向井洋平, 宮崎将行, 阿部弘基, 高橋祐二, 村田美穂

    第11回パーキンソン病・運動障害疾患コングレス(東京)  2017.10 

     More details

    Language:Japanese   Presentation type:Poster presentation  

    researchmap

  • CRMP2 binding compound, T-817-maleic-acid, accelerates motor function recovery from brain damage.

    Abe H, Jitsuki S, Nakashima W, Murata Y, Masuyama H, Komori T, Mochizuki N, Higo N, Okuda T, Takahashi T

    XXIII World Congress of Neurology(Kyoto)  2017.9 

     More details

    Language:English   Presentation type:Poster presentation  

    researchmap

  • 筋萎縮性側索硬化症を合併した統合失調症57歳女性例

    阿部弘基, 山本敏之, 木村百合香, 髙橋祐二

    難病嚥下研究会第5回セミナー(東京)  2018.4 

     More details

    Language:Japanese   Presentation type:Oral presentation (general)  

    researchmap

  • 発症早期の単純血漿交換療法が著効した中枢末梢連合脱髄症の51歳女性例

    阿部弘基, 坂本崇, 林幼偉, 金澤恭子, 山本敏之, 高橋祐二

    第224回日本神経学会関東・甲信越地方会(東京)  2018.3 

     More details

    Language:Japanese   Presentation type:Oral presentation (general)  

    researchmap

  • シナプス生理学に立脚したリハビリテーション促進薬の研究・開発

    阿部弘基, 実木亨, 中島和希, 村田弓, 実木-高橋 葵, 勝野友貴, 多田敬典, 佐野亜加根, 須山紅美子, 望月修征, 小森隆司, 増山仁, 奥田智博, 五嶋良郎, 肥後範行, 高橋琢哉

    第59回日本神経学会学術大会(札幌)  2018.5 

     More details

    Language:Japanese   Presentation type:Oral presentation (general)  

    researchmap

  • Effects of the intensive rehabilitation program in each type of degenerative cerebellar diseases

    Hiroki Abe, Kyota Bando, Yosuke Ariake, Wakana Katuta, Kyoko Ishida, Yuki Kondo, Yohei Mukai, Takashi Sakamoto, Yoko Kobayashi, Miho Murata, Yuji Takahashi

    2018.5 

     More details

    Language:English   Presentation type:Poster presentation  

    researchmap

  • Machine Learning Algorithm for Discriminating Depression and Bipolar Disorder Using [11C]K-2 AMPA Receptor PET Imaging

    Hiroki Abe, Sakiko Tsugawa, Yuichi Kimura, Junichi Chikazoe, Mai Hatano, Waki Nakajima, Hiroyuki Uchida, Tomoyuki Miyazaki, Tetsu Arisawa, Yoji Hirano, Hirotaka Kosaka, Takuya Takahashi

    2025 SOBP Annual meeting  2025.4 

     More details

    Language:English   Presentation type:Poster presentation  

    researchmap

▼display all

Research Projects

  • 失語症の機能回復ネットワークの解明

    Grant number:19K11363  2019.4 - 2024.3

    日本学術振興会  科学研究費助成事業 基盤研究(C)  基盤研究(C)

    高田 薫子, 阿部 弘基

      More details

    Authorship:Coinvestigator(s)  Grant type:Competitive

    Grant amount:\4420000 ( Direct Cost: \3400000 、 Indirect Cost:\1020000 )

    researchmap

  • Determining network for functional reorganization with AMPA receptor PET imaging technique

    Grant number:19H03980  2019.4 - 2024.3

    Japan Society for the Promotion of Science  Grants-in-Aid for Scientific Research Grant-in-Aid for Scientific Research (B)  Grant-in-Aid for Scientific Research (B)

      More details

    Grant amount:\16770000 ( Direct Cost: \12900000 、 Indirect Cost:\3870000 )

    researchmap

  • 高齢てんかん患者と早期アルツハイマー型認知症患者のAMPA受容体密度分布とアミロイドβ蓄積部位の異同を非てんかん・非認知症健常者を対象としてPET画像で検討するための探索的試験

    2021 - 2024

    エーザイ株式会社  受託研究費 (研究者主導研究) 

      More details

    Authorship:Principal investigator 

    researchmap

  • リハビリテーション効果促進薬・エドネルピクの生物学的基盤と適応拡大

    Grant number:20H00549  2020.4 - 2023.3

    日本学術振興会  科学研究費助成事業 基盤研究(A)  基盤研究(A)

    高橋 琢哉, 実木 亨, 阿部 弘基

      More details

    Grant amount:\45630000 ( Direct Cost: \35100000 、 Indirect Cost:\10530000 )

    researchmap

  • AMPA-GABA dual PET imaging による次世代型不随意運動症診断の確立

    2020 - 2024

    武田科学振興財団  ビジョナリーリサーチ助成(スタート) 

      More details

    Authorship:Principal investigator 

    researchmap

  • Neurobiological mechanisms of cerebellar macroneuroplasticity associated with learning

    Grant number:19H03536  2019.4 - 2022.3

    Japan Society for the Promotion of Science  Grants-in-Aid for Scientific Research Grant-in-Aid for Scientific Research (B)  Grant-in-Aid for Scientific Research (B)

      More details

    Grant amount:\17680000 ( Direct Cost: \13600000 、 Indirect Cost:\4080000 )

    researchmap

▼display all

Teaching Experience

Social Activities

  • 地域医療におけるMCI・早期ADの診かた・考えかた

    Role(s): Appearance

    エーザイ株式会社/バイオジェン・ジャパン株式会社  綾瀬市における認知症診療を考える会  2025.2

     More details

    Type:Lecture

    researchmap

  • 綾瀬厚生病院における認知症診療について 〜地域生活を支えるために事例を通して学ぶ診療の実際〜

    綾瀬市役所福祉部地域包括ケア推進課  (認知症に関する研修会)  2022.3

     More details

    Type:Lecture

    researchmap